04/26/2013 04:54:10
Cryme Trainer (moved)
Non-HLA-linked Diseases
Hurricane Sandy and Mold-Related
illnesses (like LYMErix and Lyme Disease, and CFIDS/FM).
=======
References for psychotropics-induced brain damage
Older data on the incurability of Relapsing Fever
1986, McSweegan trashes Navy for $$$ for ALDF.com
1988, Dattwyler & about immune-suppressing, seronegative Lyme
1990, CDC: "Diagnose Lyme as if it was Relapsing Fever."
Allen Steere "NeuroLyme won't test positive," 1990.
1992, CDC officer Allen Steere falsifies testing in Europe
1992, CDC patents with SmithKline show 2 kinds of Lyme
Compare the 2 kinds of Lyme in the RICO complaint
1994, CDC's Dearborn Booklet .pdf
CDC's invitation to participate in Dearborn .pdf
Evidence Lyme criminals knew LYMErix produced the same "multisystem disease" as "Chronic Lyme"
LYMErix Damage Coverup
(short)
1998, CIA Oilmen & Israelis plan to overthrow Saddam for the oil.
Bush/Gore Oil/War-(Oct,2000)
Bush's own explainer (Oct
2000) re:
Iraq Oil
BACK TO THE 1989 IDSA REVIEWS, SPECIAL SUPPLEMENTIncluded in that Supplement are these articles about syphilis and spirochetes in general
Rev Infect Dis. 1989 Sep-Oct;11 Suppl 6:S1511-7.
Treatment of syphilis: current recommendations, alternatives, and continuing problems.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Benzathine penicillin continues to be the cornerstone of recommended therapy for syphilis. Recent increases in the syphilis rates in the United States and concerns about the adequacy of currently recommended therapy for syphilis in patients with concomitant human immunodeficiency virus infection have stimulated reappraisal of alternatives to currently recommended therapy. Desirable features of antimicrobial agents for syphilotherapy include long serum half-life, good penetration into the central nervous system, and ease of administration. Benzathine penicillin provides prolonged treponemicidal levels of penicillin G in serum but does not reliably produce adequate levels of penicillin in the central nervous system. Tetracycline requires multiple daily dosing, has relatively frequent adverse effects, and has unproven efficacy for central nervous system involvement. Erythromycin, which may be less active than tetracycline for syphilis therapy, has similar shortcomings. Recent evaluations of ceftriaxone for early syphilis therapy are promising; however, the optimal dose and duration of therapy are unknown. No currently recommended therapy for syphilis is clearly optimal for reliable, cost-effective therapy. Careful reappraisal of currently available syphilotherapy and alternatives is needed. PMID: 2682964 [PubMed - indexed for MEDLINE]
Rev Infect Dis. 1989 Sep-Oct;11 Suppl 6:S1511-7.
Treatment of syphilis: current recommendations, alternatives, and continuing problems.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Benzathine penicillin continues to be the cornerstone of recommended therapy for syphilis. Recent increases in the syphilis rates in the United States and concerns about the adequacy of currently recommended therapy for syphilis in patients with concomitant human immunodeficiency virus infection have stimulated reappraisal of alternatives to currently recommended therapy. Desirable features of antimicrobial agents for syphilotherapy include long serum half-life, good penetration into the central nervous system, and ease of administration. Benzathine penicillin provides prolonged treponemicidal levels of penicillin G in serum but does not reliably produce adequate levels of penicillin in the central nervous system. Tetracycline requires multiple daily dosing, has relatively frequent adverse effects, and has unproven efficacy for central nervous system involvement. Erythromycin, which may be less active than tetracycline for syphilis therapy, has similar shortcomings. Recent evaluations of ceftriaxone for early syphilis therapy are promising; however, the optimal dose and duration of therapy are unknown. No currently recommended therapy for syphilis is clearly optimal for reliable, cost-effective therapy. Careful reappraisal of currently available syphilotherapy and alternatives is needed. PMID: 2682964 [PubMed - indexed for MEDLINE]
